Scarica l'app Stockscreener
1.16
1.69%
-0.02
Dopo l'orario di chiusura:
1.17
0.01
+0.86%
Precedente Chiudi:
$1.18
Aprire:
$1.17
Volume 24 ore:
4.39M
Relative Volume:
1.41
Capitalizzazione di mercato:
$311.17M
Reddito:
$236.20M
Utile/perdita netta:
$-5.35M
Rapporto P/E:
-64.80
EPS:
-0.0179
Flusso di cassa netto:
$67.70M
1 W Prestazione:
-17.14%
1M Prestazione:
-18.88%
6M Prestazione:
-43.14%
1 anno Prestazione:
-55.73%
Intervallo 1D:
$1.125
$1.20
Intervallo di 1 settimana:
$1.125
$1.54
Portata 52W:
$1.125
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.16 | 316.54M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.57B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.93B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.11 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.83 | 36.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
564.94 | 24.16B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Akebia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia (AKBA) Q1 2026 Earnings Transcript - AOL.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA): Is Breakeven Near? - Moomoo
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript - GuruFocus
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Zacks Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Akebia Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Akebia plunges 20% on muted Q1 print - MSN
Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Akebia Therapeutics Q1 Earnings Call Highlights - MarketBeat
Akebia Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Earnings call transcript: Akebia’s Q1 2026 results miss forecasts, stock drops - Investing.com Canada
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance UK
Akebia Therapeutics (NASDAQ: AKBA) swings to Q1 2026 loss amid new Auryxia generic - Stock Titan
Akebia Therapeutics: Q1 Earnings Snapshot - KVUE
Akebia (NASDAQ: AKBA) Q1 2026 loss amid Auryxia decline, Vafseo growth - Stock Titan
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - Yahoo Finance
Akebia Q1 2026 earnings preview - MSN
MSN Money - MSN
Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology - 富途牛牛
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Moomoo
Akebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
AKBA Forecast, Price Target & Analyst Ratings | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill
Earnings Preview: AKBA to Report Financial Results Pre-market on May 07 - Moomoo
Are options traders betting on a big move in Akebia Therapeutics stock? - MSN
Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan
Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Akebia (AKBA) Road Ahead | Q4 2025: EPS Misses ViewsCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
Akebia (AKBA) Stock: Long-Term Outlook Review (Steady Climb) 2026-04-20Verified Analyst Reports - Cổng thông tin điện tử tỉnh Tây Ninh
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 - GuruFocus
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Potential Upside of 225.93% Draws Investor Attention - DirectorsTalk Interviews
AKBA Should I Buy - Intellectia AI
Akebia Therapeutics (NASDAQ: AKBA) asks shareholders to increase authorized stock - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com - Investing.com Australia
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Sahm
Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid - GuruFocus
Akebia doses first patients in Phase 1 trial of AKB-9090 - Investing.com Canada
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - The Manila Times
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.49%
1.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):